Cogent Biosciences (COGT) – Globe Newswire
-
Cogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 Inhibitor
-
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
-
Cogent Biosciences Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis
-
Cogent Biosciences Announces Oversubscribed $225 Million Private Placement
-
Cogent Biosciences to Present SUMMIT Part 1b Data with Bezuclastinib in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2024 AAAAI Annual Meeting
-
Cogent Biosciences Announces Planned 2024 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Therapeutics
-
Cogent Biosciences Announces Presentation at the 42nd Annual J.P. Morgan Healthcare Conference
-
Cogent Biosciences Announces Positive Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
-
Cogent Biosciences Announces Positive Initial Data from Phase 2 SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM)
-
Cogent Biosciences Presents New Preclinical Data Highlighting Potential Best-in-Class Potency and Selectivity of ErbB2 and PI3Kα inhibitor programs at the San Antonio Breast Cancer Symposium
-
Cogent Biosciences to Host Investor Webcast on December 11, 2023 at 8:00 AM ET to Review Clinical Data Being Presented at American Society of Hematology (ASH) Annual Meeting
-
Cogent Biosciences Announces Poster Presentations at Upcoming San Antonio Breast Cancer Symposium
-
Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2023 Financial Results
-
Cogent Biosciences Presents Preclinical Data Highlighting Precision Oncology Pipeline at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
-
Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2023 Financial Results
-
Cogent Biosciences Announces Closing of Upsized Public Offering of Common Stock
-
Cogent Biosciences Announces Participation in the Jefferies Healthcare Conference
-
Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock
-
Cogent Biosciences Announces Proposed Public Offering of Common Stock
-
Cogent Biosciences Announces Positive Lead-In Data from Ongoing Phase 3 PEAK Trial Evaluating Bezuclastinib in Combination with Sunitinib in Patients with Gastrointestinal Stromal Tumors (GIST)
-
Cogent Biosciences to Host Investor Webcast to Discuss Lead-In Data Being Presented at ASCO from the Ongoing Phase 3 PEAK Trial in Patients with Gastrointestinal Stromal Tumors (GIST)
-
Cogent Biosciences Reports Recent Business Highlights and First Quarter 2023 Financial Results
-
Cogent Biosciences Presents Preclinical Data at AACR Annual Meeting Highlighting Precision Therapy Pipeline and Announces Initiation of Part 2 of the Registration-Enabling APEX Trial with Bezuclastini
-
Cogent Biosciences Announces Participation at Upcoming Investor Conferences
-
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results
-
Cogent Biosciences Announces Participation at Upcoming Investor Conferences
-
Cogent Biosciences Announces Planned 2023 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Cancer Therapeutics
-
Cogent Biosciences Announces Presentation at the 41st Annual J.P. Morgan Healthcare Conference
-
Cogent Biosciences Announces Positive Updated Clinical Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
-
Cogent Biosciences to Host Investor Webcast to Discuss Updated Clinical Data at ASH from the Ongoing Phase 2 APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis
-
Cogent Biosciences Appoints Rachael Easton, MD, Ph.D., VP, Head of Clinical Development
-
Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2022 Financial Results
-
Cogent Biosciences Announces Participation at Upcoming Investor Conferences
-
Cogent Biosciences Announces Bezuclastinib Presentations at the 64th Annual American Society of Hematology (ASH) Meeting
-
Cogent Biosciences to Showcase Precision Therapy Pipeline at the EORTC-NCI-AACR Annual Meeting
-
Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2022 Financial Results
-
Cogent Biosciences Announces Closing of Upsized Public Offering of Common Stock and Pre-funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock and Pre-funded Warrants
-
Cogent Biosciences Announces Proposed Public Offering of Common Stock
-
Cogent Biosciences Announces Positive Initial Clinical Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
-
Cogent Biosciences to Host Investor Webcast on June 10, 2022 at 8:00am ET
-
Cogent Biosciences Announces Annual Meeting of Stockholders
-
Cogent Biosciences Announces Presentation at European Hematology Association (EHA) Annual Congress
-
Cogent Biosciences Reports Recent Business Highlights and First Quarter 2022 Financial Results
-
Cogent Biosciences to Participate in the LifeSci Partners Immunology and Inflammation Symposium
-
Cogent Biosciences Presents Nonclinical Data at AACR Annual Meeting and Provides Updates on Portfolio Expansion at R&D Investor Event
-
Cogent Biosciences to Host Virtual R&D Investor Event
-
Cogent Biosciences Provides Corporate Updates, Fourth Quarter and Full Year 2021 Financial Results
-
Cogent Biosciences Announces Upcoming Presentations at AACR Annual Meeting 2022
Back to COGT Stock Lookup
